Contrasting MacroGenics (NASDAQ:MGNX) & Intellia Therapeutics (NASDAQ:NTLA)

MacroGenics (NASDAQ:MGNX) and Intellia Therapeutics (NASDAQ:NTLA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, earnings, analyst recommendations, institutional ownership, profitability and risk.

Valuation and Earnings

This table compares MacroGenics and Intellia Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MacroGenics	$149.50 million	1.03	-$74.62 million	($0.22)	-11.00
Intellia Therapeutics	$52.89 million	29.64	-$412.69 million	($3.35)	-3.33

MacroGenics has higher revenue and earnings than Intellia Therapeutics. MacroGenics is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

MacroGenics has a beta of 1.33, meaning that its stock price is 33% more volatile than the S&P 500. Comparatively, Intellia Therapeutics has a beta of 1.83, meaning that its stock price is 83% more volatile than the S&P 500.

Institutional & Insider Ownership

96.9% of MacroGenics shares are held by institutional investors. Comparatively, 88.8% of Intellia Therapeutics shares are held by institutional investors. 13.6% of MacroGenics shares are held by company insiders. Comparatively, 3.5% of Intellia Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and price targets for MacroGenics and Intellia Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MacroGenics	1	1	3	0	2.40
Intellia Therapeutics	4	7	9	1	2.33

MacroGenics currently has a consensus price target of $8.50, suggesting a potential upside of 251.24%. Intellia Therapeutics has a consensus price target of $21.44, suggesting a potential upside of 91.98%. Given MacroGenics’ stronger consensus rating and higher probable upside, research analysts clearly believe MacroGenics is more favorable than Intellia Therapeutics.

Profitability

This table compares MacroGenics and Intellia Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MacroGenics	-8.70%	-109.26%	-18.70%
Intellia Therapeutics	-805.75%	-64.74%	-50.72%

Summary

MacroGenics beats Intellia Therapeutics on 9 of the 15 factors compared between the two stocks.

About MacroGenics

MacroGenics, Inc. is a biopharmaceutical company focused on developing antibody-based therapies for cancer and immune-mediated diseases. Headquartered in Rockville, Maryland, the company uses its proprietary DART platform and other antibody technologies to create treatments designed to modulate immune responses and target disease-associated cells. MacroGenics’ portfolio includes MARGENZA (margetuximab-cmkb), an antibody therapy approved in the United States for certain patients with HER2-positive metastatic breast cancer.

About Intellia Therapeutics

Intellia Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing genome-editing treatments for serious diseases. Founded in 2014 and headquartered in Cambridge, Massachusetts, the company uses CRISPR/Cas9 technology to make targeted changes to DNA. Its research includes in vivo therapies, which are designed to edit genes inside a patient’s body, and ex vivo approaches, which involve modifying cells outside the body before they are returned to the patient. Intellia’s investigational programs have included treatments for transthyretin amyloidosis and hereditary angioedema.